The estimated Net Worth of Nassim Usman is at least 1.21 百万$ dollars as of 9 August 2022. Nassim Usman owns over 3,250 units of Catalyst Biosciences Inc stock worth over 12,516$ and over the last 9 years he sold CBIO stock worth over 0$. In addition, he makes 1,198,860$ as President、 Chief Executive Officer、 Director at Catalyst Biosciences Inc.
Nassim has made over 12 trades of the Catalyst Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 3,250 units of CBIO stock worth 1,528$ on 9 August 2022.
The largest trade he's ever made was exercising 5,729 units of Catalyst Biosciences Inc stock on 31 January 2019 worth over 26,525$. On average, Nassim trades about 1,324 units every 90 days since 2015. As of 9 August 2022 he still owns at least 24,541 units of Catalyst Biosciences Inc stock.
You can see the complete history of Nassim Usman stock trades at the bottom of the page.
Dr. Nassim Usman Ph.D. serves as President, Chief Executive Officer, Director of the Company. Since the merger, Dr. Usman has served as our President and Chief Executive Officer and as a Class III director. Effective immediately prior to the Annual Meeting, Dr. Usman was reclassified as a Class II director. Dr. Usman is currently a Venture Partner at Morgenthaler Ventures. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc., which was subsequently acquired by Merck, from 2004 to 2005, and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals, including Vice President of R&D and Chief Scientific Officer, from 1992 to 2004. During his industrial career, Dr. Usman has overseen the entry of several drugs into clinical development, completion of multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to moving into the private sector in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and is the named inventor in 130 issued patents and patent applications. Dr. Usman serves on the board of directors of Mosaic Biosciences, is a past director of Principia Biopharma, Osprey Pharmaceuticals, Archemix Corporation and atugen AG (now Silence Therapeutics) and served on the science advisory boards of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation, he developed a method for the solid-phase synthesis of RNA that is widely used in science and in two marketed RNA products (Macugen™ & Onpattro™).
As the President、 Chief Executive Officer、 Director of Catalyst Biosciences Inc, the total compensation of Nassim Usman at Catalyst Biosciences Inc is 1,198,860$. There are no executives at Catalyst Biosciences Inc getting paid more.
Nassim Usman is 60, he's been the President、 Chief Executive Officer、 Director of Catalyst Biosciences Inc since 2015. There are 7 older and 1 younger executives at Catalyst Biosciences Inc. The oldest executive at Catalyst Biosciences Inc is Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D., 67, who is the Consultant.
Nassim's mailing address filed with the SEC is 260 Littlefield Ave, South San Francisco, CA 94080, USA.
Over the last 9 years, insiders at Catalyst Biosciences Inc have traded over 2,614,728$ worth of Catalyst Biosciences Inc stock and bought 81,771 units worth 199,380$ . The most active insiders traders include Jeff Himawan、James E Deerfield Mgmt L.P....、Augustine Lawlor. On average, Catalyst Biosciences Inc executives and independent directors trade stock every 62 days with the average trade being worth of 3,315$. The most recent stock trade was executed by Nassim Usman on 9 August 2022, trading 3,250 units of CBIO stock currently worth 1,528$.
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
Catalyst Biosciences Inc executives and other stock owners filed with the SEC include: